Results 221 to 230 of about 224,992 (367)

Outcome of Patients With Lupus Nephritis Treated With an Anti‐CD40 Monoclonal Antibody According to Kidney Biopsy Features

Arthritis &Rheumatology, Volume 77, Issue 6, Page 696-704, June 2025.
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo, Helmut Schumacher, Juergen Steffgen, Simone Deutschel, David Jayne, Ingeborg Bajema   +5 more
wiley   +1 more source

Potassium-losing Nephritis Presenting as a Case of Periodic Paralysis [PDF]

, 1954
B. M. Evans, M. D. Milne
openalex   +1 more source

Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species

Arthritis &Rheumatology, Volume 77, Issue 6, Page 705-715, June 2025.
Objective Cutaneous lupus erythematosus (CLE) is an inflammatory skin manifestation of systemic lupus erythematosus. Type I interferons (IFNs) promote inflammatory responses and are elevated in CLE lesions. We recently reported that CLE lesions are frequently colonized with Staphylococcus aureus.
Lisa Abernathy‐Close, Joseph Mears, Allison C. Billi, Sirisha Sirobhushanam, Celine Berthier, Annie Lu, Zeran Zhang, Amy Hurst, Johann E. Gudjonsson, J. Michelle Kahlenberg   +9 more
wiley   +1 more source

Experimenteller Beitrag zur Erkenntnis der bei Nephritis auftretenden Hypertrophie des linken Herzens [PDF]

, 1905
M. Katzenstein
openalex   +1 more source

Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis

Proceedings of the National Academy of Sciences of the United States of America, 2010
Abdul Hakkim, B. Fürnrohr, K. Amann, B. Laube, U. Abed, V. Brinkmann, M. Herrmann, R. Voll, A. Zychlinsky   +8 more
semanticscholar   +1 more source

Serum and urinary biomarkers in lupus nephritis: do suPAR and VEGF play a role? [PDF]

J Bras Nefrol
Piraciaba TT, Riguetti MTP, Kirsztajn GM.   +2 more
europepmc   +1 more source

Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10‐Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission

Arthritis &Rheumatology, Volume 77, Issue 6, Page 716-726, June 2025.
Objective Cardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10‐year follow‐up.
Nikolaos Papazoglou, Petros P. Sfikakis, Maria G. Tektonidou   +2 more
wiley   +1 more source

EXPERIMENTAL NEPHRITIS IN RATS INDUCED BY INJECTION OF ANTIKIDNEY SERUM [PDF]

, 1941
Joseph E. Smadel, Homer F. Swift
openalex   +1 more source

Voclosporin: A comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus. [PDF]

Medicine (Baltimore)
Ashinze P, Mafua N, Banerjee S, Obafemi E, Eniola A, Emmanuel E, Edache AO, Ozioma CB, Wireko AA, Abdul-Rahman T.   +9 more
europepmc   +1 more source

A Study on the Neurological Mechanisms of the Impact of Different Dialysis Methods on Brain Structure and Functional Network Dynamic Reorganization in Patients With End‐Stage Renal Disease Undergoing Dialysis

Brain and Behavior, Volume 15, Issue 6, June 2025.
Hemodialysis outperforms peritoneal dialysis in renal clearance and enhances brain default mode network activity, suggesting dual benefits of renal function improvement and neuroprotection. ABSTRACT Introduction End‐stage renal disease (ESRD) is a severe condition that necessitates dialysis.
Hui Han, Huijuan Chen, Ying Zhang, Jiali Wei   +3 more
wiley   +1 more source